文献速递精神分裂症与精神病性障碍

精神分裂症与神经递质通路遗传负荷对首发未用药患者神经认知及抗精神病药疗效的独立贡献

Distinct contributions of schizophrenia and neurotransmitter pathway genetic liability to neurocognition and antipsychotic efficacy in drug-naïve first-episode schizophrenia.
PubMed 文献 · Mol Psychiatry · 2026-06-15

该研究在394例首发未用药精神分裂症患者中整合全基因组精神分裂症多基因风险评分(SZ-PRS)与四种主要神经递质系统的通路特异性PRS(pPRS),考察其与基线症状、神经认知及52周纵向疗效的关联。结果显示SZ-PRS预测诊断及基线执行功能和工作记忆更差,而pPRS对治疗结局更具信息量:血清素-pPRS预测抑郁症状改善更明显,GABA-pPRS预测总体症状改善更明显。

要点

  • SZ-PRS预测精神分裂症诊断(OR=2.28)及更差的基线执行功能(β=-0.44)和工作记忆(β=-0.49),健康成人中无此关联。
  • 血清素-pPRS预测第4-24周抑郁症状改善更明显(Pfdr=0.023-0.032)。
  • GABA-pPRS预测第4-24周总体症状改善更明显(Pfdr=0.038-0.043)。

核心结论

  • 全基因组与通路特异性PRS对精神分裂症表型贡献不同,支持整合二者用于个体化分层和治疗。

研究设计与样本

  • 主要分析纳入中国首发精神分裂症试验(CNFEST)中394例未用药首发患者,进行52周纵向评估。
  • 采用阳性和阴性症状量表及改良版MATRICS共识认知成套测验评估症状和神经认知。
  • 另设独立病例对照队列评估与诊断的关联,以及514名健康成人队列评估PRS-认知关联是否精神分裂症特异。

主要发现

  • 较高的SZ-PRS预测精神分裂症诊断(OR=2.28,Pfdr=0.003)。
  • 较高的SZ-PRS预测更差的基线执行功能(β=-0.44,Pfdr=0.006)和工作记忆(β=-0.49,Pfdr=0.018)。
  • SZ-PRS与认知的关联在健康成人中不存在。
  • pPRS与诊断和基线认知关联较弱,但对治疗结局更具信息量。
  • 较高的血清素-pPRS预测第4-24周抑郁症状改善更明显(Pfdr=0.023-0.032)。

关键数值与推荐

  • SZ-PRS与诊断关联:OR=2.28,Pfdr=0.003。
  • SZ-PRS与基线执行功能关联:β=-0.44,Pfdr=0.006。
  • SZ-PRS与基线工作记忆关联:β=-0.49,Pfdr=0.018。
  • 血清素-pPRS与第4-24周抑郁症状改善关联:Pfdr=0.023-0.032。
  • GABA-pPRS与第4-24周总体症状改善关联:Pfdr=0.038-0.043。

临床怎么用

  • SZ-PRS可能有助于识别基线神经认知损害更重的首发患者。
  • 血清素-pPRS和GABA-pPRS可能为早期治疗结局的个体化预测提供信息。
  • 探索性药物特异性分析提示疗效因抗精神病药而异并与pPRS差异关联,尚需进一步验证。

局限性

  • 原文未报告局限性相关内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The genetic mechanisms underlying heterogeneity in symptom presentation and antipsychotic response in schizophrenia remain unclear, limiting the development of personalized treatment. We integrated genome-wide schizophrenia polygenic risk scores (SZ-PRS) and pathway-specific PRSs (pPRSs) for four major neurotransmitter systems to examine their associations with clinical phenotypes across the course of illness. Primary analyses were conducted in 394 drug-naïve, first-episode patients from the Chinese First-Episode Schizophrenia Trial (CNFEST) to investigate associations with baseline symptom severity, neurocognitive impairment, and longitudinal treatment response. The CNFEST cohort included 52-week longitudinal assessments of symptoms and neurocognition using the Positive and Negative Syndrome Scale and a modified version of the MATRICS Consensus Cognitive Battery. An independent case-control cohort evaluated associations with schizophrenia diagnosis, while a cohort of 514 healthy adults assessed whether PRS-cognition associations are specific to schizophrenia. Higher SZ-PRS predicted schizophrenia diagnosis (OR = 2.28, Pfdr = 0.003) and poorer baseline executive function (β = -0.44, Pfdr = 0.006) and working memory (β = -0.49, Pfdr = 0.018), but these associations were absent in healthy adults. In contrast, pPRSs showed weaker associations with diagnosis and baseline cognition but were more informative for treatment outcomes: higher serotonin-pPRS predicted greater improvement in depressive symptoms (Pfdr = 0.023-0.032), and higher GABA-pPRS predicted greater improvement in overall symptoms (Pfdr = 0.038-0.043) during weeks 4-24. Exploratory drug-specific analyses further suggested that treatment response varied across antipsychotics and was differentially associated with pPRSs. These findings demonstrate that genome-wide and pathway-specific PRSs contribute distinctly to schizophrenia phenotypes, supporting their integration for personalized stratification and treatment.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Yu T, Lu Z, Huang B, et al. Distinct contributions of schizophrenia and neurotransmitter pathway genetic liability to neurocognition and antipsychotic efficacy in drug-naïve first-episode schizophrenia. Mol Psychiatry. 2026. PMID: 42297934. doi:10.1038/s41380-026-03684-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。